7-Azabicyclo\x9b2.2.1!-heptane and -heptene derivatives as cholinergic
申请人:University of Virginia
公开号:US05817679A1
公开(公告)日:1998-10-06
7-Aza-bicyclo\x9b2.2.1!-heptane and -heptene derivatives are disclosed that can be administered to a mammal, including a human, to treat disorders associated with a decrease or increase in cholinergic activity.
Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases
申请人:Cormier Yvon
公开号:US20080221085A1
公开(公告)日:2008-09-11
Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.
7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic
申请人:UCB S.A. - DTB
公开号:US06060473A1
公开(公告)日:2000-05-09
7-Azabicyclo[2.2.1]-heptane and -heptene derivatives are disclosed that can be administered to a mammal, including a human, to treat disorders associated with a decrease or increase in cholinergic activity.
7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and
申请人:University of Virginia
公开号:US06117889A1
公开(公告)日:2000-09-12
7-Azabicyclo[2.2.1]-heptane and -heptene derivatives with analgesic or anti-inflammatory activity are disclosed that can be administered to a mammal, including a human, to treat pain and inflammatory disorders. A method for the treatment of pain or inflammatory disorders is also presented that includes administering an effective amount of the compound or its pharmaceutically acceptable salt or derivative, or mixtures thereof, to a host in need of analgesic anti-inflammatory therapy, optionally in a pharmaceutically acceptable carrier or diluent.
NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
申请人:CORMIER Yvon
公开号:US20110301152A1
公开(公告)日:2011-12-08
Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.